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Abstract
Background: Cholangiocarcinoma is an aggressive tumor with a tendency for local invasion and
distant metastases. Timely diagnosis is very important because surgical resection (R0) remains the
only hope for a cure. However, at present, there is no available tumor marker that can differentiate
cholangiocarcinoma from benign bile duct disease. Previous studies have demonstrated that matrix
metalloproteinase (MMP)-7 and MMP-9 are frequently expressed in cholangiocarcinoma
specimens.
Methods: This study was designed to determine whether the serum levels of MMP-7 and MMP-9
can discriminate cholangiocarcinoma patients from benign biliary tract disease patients in
comparison to carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9). We
measured the level of CEA, CA19-9, MMP-7 and MMP-9 in the serum of 44 cholangiocarcinoma
and 36 benign biliary tract diseases patients.
Results: Among the serum levels of CEA, CA19-9, MMP-7 and MMP-9, only the serum MMP-7
level was significantly higher in the patients with cholangiocarcinoma (8.9 ± 3.43 ng/ml) compared
to benign biliary tract disease patients (5.9 ± 3.03 ng/ml) (p < 0.001). An receiver operating
characteristic (ROC) curve analysis revealed that the detection of the serum MMP-7 level is
reasonably accurate in differentiating cholangiocarcinoma from benign biliary tract disease patients
(area under curve = 0.73; 95% CI = 0.614–0.848). While the areas under the curve of the ROC
curves for CEA, CA19-9 and MMP-9 were 0.63 (95% CI = 0.501–0.760), 0.63 (95% CI = 0.491–
0.761) and 0.59 (95% CI = 0.455–0.722), respectively.
Conclusion: Serum MMP-7 appears to be a valuable diagnostic marker in the discrimination of
cholangiocarcinoma from benign biliary tract disease. Further prospective studies for serum MMP-
7 measurement should be carried out to further investigate the potential of this molecule as a
biomarker of cholangiocarcinoma.
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Background
The incidence of and mortality rate for cholangiocarci-
noma varies considerably among different geographic
regions, with the highest incidence being observed in
Southeast Asia, especially in Thailand [1]. In the United
States, the most commonly recognized risk factor for
cholangiocarcinoma is primary sclerosing cholangitis
(PSC) [2,3]. However, in Southeast Asia and especially in
Thailand, infection with hepatobiliary flukes (Opisthorchis
viverrini) is the most common risk factor for cholangiocar-
cinoma [4]. Therapeutic options for cholangiocarcinoma
have been limited since this type of cancer responds
poorly to chemotherapy and radiation therapy. Surgery is
perhaps the only effective treatment for cholangiocarci-
noma. Five-year survival, which typically has a rate
between 32% and 50%, is achieved by only a small
number of patients when negative histological margins
are attained at the time of surgery [5]. To improve the sur-
vival rate, patients must be diagnosed and treated as early
in the disease onset as possible.
To properly diagnose cholangiocarcinoma, it is very diffi-
cult to get to the tissue due to the tumor location and the
desmoplastic reaction. In addition, this tumor typically
grows along the bile duct without expanding from the bile
ducts as a forming mass. Computed tomography (CT),
ultrasound, and magnetic resonance imaging (MRI) often
miss this lesion [6]. Therefore, identification of tumor
markers in the serum would be beneficial in the clinical
management of this disease. To date, there are two com-
mon tumor markers used for detecting cholangiocarci-
noma, carcinoembryonic antigen (CEA) and
carbohydrate antigen 19-9 (CA19-9). CEA is unspecific
and can be elevated in the setting of other gastrointestinal
or gynecologic malignancies or other bile duct patholo-
gies, such as cholangitis and hepatolithiasis [7]. Previous
studies have demonstrated that the sensitivity and specif-
icity of a CA 19-9 value >100 U/ml for cholangiocarci-
noma in primary sclerosing cholangitis (PSC) are 89%
and 86%, respectively [8,9]. However, a cut-off of the CA
19-9 value at 100 U/ml resulted in a sensitivity of only
53.0–67.5% for diagnosing cholangiocarcinoma in
patients without PSC [10,11]. In addition, a previous
study demonstrated that the level of serum CA19-9 is
dependent on the severity of the bile duct obstruction and
the degree of cholangitis. An increase in the serum level of
CA19-9 can be detected even in benign bile duct diseases
[12,13]. Therefore, novel tumor markers should be inves-
tigated to better diagnose cholangiocarcinoma in patients
with or without PSC.
Typically, tumor cells invade the basement membrane by
secreting enzymes that digest the extracellular matrix pro-
teins. These enzymes are known as matrix metalloprotei-
nase (MMPs). MMPs are zinc-dependent endopeptidases.
They are involved in the turnover and degradation of the
extracellular matrix (ECM) components and basement
membranes [14]. Recently, Itatsu K, et al. examined the
expression of MMPs in surgically resected specimens of
cholangiocarcinoma using an immunohistochemical
method and found that 47.5 and 75.8% of these speci-
mens expressed MMP-9 and MMP-7, respectively [15].
Previous studies have demonstrated that MMP-9 can be
detected in the serum of gastric cancer patients and MMP-
7 is increased in colorectal, ovarian and renal cancer
patients [16-19]. Therefore, detection of MMP-9 and
MMP-7 in the blood circulation may be useful for the clin-
ical diagnosis of cholangiocarcinoma. To date, there is no
published study on the detection of serum levels of MMP-
9 and MMP-7 in cholangiocarcinoma patients. The objec-
tive of this study was to determine the accuracy of detect-
ing serum levels of MMP-9 and MMP-7 for the diagnosis
of cholangiocarcinoma in patients without primary scle-
rosing cholangitis.
Methods
Patients and samples
Pre-treatment fasting serum samples (n = 80) were col-
lected from obstructive jaundice patients who underwent
endoscopic retrograde cholangiography (ERCP) or biliary
tract surgery at Rajavithi Hospital. All patient sera and
clinical information were obtained with patient consent
after approval by Rajavithi Ethics Committee. Thirty-six
patients were diagnosed with benign biliary tract diseases,
and 44 patients were diagnosed as having cholangiocarci-
noma by one of the following criteria: 1) tissue biopsy (n
= 7), 2) cytology (n = 17), and 3) radiological finding
(helical CT scan or MRI) and clinical observation to iden-
tify the progression of the tumor at follow up (n = 20).
Serum samples from these patients were separated by cen-
trifugation within 2 h and frozen at -80°C. The biochem-
ical studies of serum samples, including AST, ALT, total
and direct bilirubin, alkaline phosphatase (ALP), CEA and
CA19-9, were measured using routine automated meth-
ods in the Pathological Laboratory at Rajavithi Hospital.
Measurement of serum MMP-7 and MMP-9
Serum MMP-9 and MMP-7 levels were measured using an
enzyme-linked immunosorbent assay (ELISA) kit (R&D
Systems, Minneapolis, MN). The diluted serum samples
were added in duplicate to 96-well plates coated with the
MMP-9 or MMP-7 antibody and incubated at room tem-
perature for 2 h. After washing three times with washing
buffer, the conjugated secondary antibody was added, and
the plate was further incubated for 2 h. Plates were washed
again prior to incubation with the substrate solution for 1
h. The amplifier solution was then added, and the plate
was incubated for an additional 30 min. All incubation
cycles were performed at room temperature. Following
termination of the reaction with the stop solution (1 NBMC Gastroenterology 2009, 9:30 http://www.biomedcentral.com/1471-230X/9/30
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sulfuric acid), the optical density was measured at 490 nm
using a spectrophotometric microplate reader. The con-
centration of MMP-9 and MMP-7 in each sample was cal-
culated from a standard curve.
Statistical analysis
Comparison between the quantitative variables was per-
formed by using Mann-Whitney U or Student's t-test, as
appropriate. Qualitative variables were reported as
counts, and comparisons between independent groups
were performed by using by Pearson Chi-square. The diag-
nostic accuracy of each of the candidate biomarkers was
evaluated using receiver operating characteristic (ROC)
curve analysis, which correlates true- and false-positive
rates [sensitivity and (1-specificity)]. In addition, an area
under the ROC curve (AUC) with 95% confidence inter-
vals (CI) was calculated for each marker. The optimal cut-
off points for MMP-9 and MMP-7 were selected based on
the ROC curve analysis. Sensitivity, specificity, positive
predictive value and negative predictive value were calcu-
lated using a 2 × 2 table of the collected data.
Results
Patient Characteristics
In cholangiocarcinoma cases, there were 12 cases of intra-
hepatic cholangiocarcinoma and 32 cases of perihilar
cholangiocarcinoma. Primary or secondary common bile
duct stones (78%; n = 28) were the most common dis-
eases in the control patients. The clinical characteristics of
the patients in this study are shown in Table 1. No statis-
tically significant differences were found among the data
of the patients considered as controls and those with
cholangiocarcinoma regarding gender, age, serum albu-
min, globulin and ALT levels. However, the level of serum
AST, bilirubin and alkaline phosphatase were significantly
higher in cholangiocarcinoma patients than in controls
(Mann-Whitney U test; p < 0.05).
Detection of CEA and CA19-9 in serum of 
cholangiocarcinoma and benign obstructive jaundice 
patients
The median CEA and CA19-9 values in the control group
were 3.96 ng/ml (range; 0.56–260.24) and 45.88 U/ml
(range 0.60–10000.00), respectively. The median CEA
and CA19-9 values in the cholangiocarcinoma group were
8.27 ng/ml (range; 0.85–131.70) and 2176.00 U/ml
(range; 0.50–10000.00), respectively. However, there was
no statistically significant difference in the levels of these
two markers between the control and cholangiocarci-
noma patients (Mann-Whitney U test; p = 0.057 for CEA
and p = 0.056 for CA19-9). These data are shown in Figure
1. We used a CEA cut-off value of 5 ng/ml and a CA19-9
cut-off value of 100 U/ml because these have been the
suggested cut-off value for the diagnosis of cholangiocar-
cinoma [7]. Using a CEA cut-off value of 5 ng/ml, the sen-
sitivity was determined to be 58.54% (CI 95% 43.37 –
72.24), and the specificity was determined to be 62.50%
(CI 95% 45.25 – 77.07). Using a CA19-9 cut-off value of
100 U/ml, the sensitivity was determined to be 70.45%
(CI 95% 55.78 – 81.84), and the specificity was deter-
mined to be 63.64% (CI 95% 46.62 – 77.81).
Detection of MMP-9 and MMP-7 in serum of 
cholangiocarcinoma and benign obstructive jaundice 
patients
There was no statistically significant difference in the lev-
els of MMP-9 between the control (mean ± SD; 16.5 ±
9.30 ng/ml) and cholangiocarcinoma patients (mean ±
SD; 18.9 ± 8.55 ng/ml), (Student's t-test; p = 0.251, 95%
CI -1.74–6.55). In contrast, the serum MMP-7 values in
the cholangiocarcinoma patients (mean ± SD; 8.9 ± 3.43
ng/ml) were significantly higher than those in the control
patients (mean ± SD; 5.9 ± 3.03 ng/ml), (Student's t-test;
p < 0.001, 95% CI 1.34–4.47).
Table 1: Clinical characteristics of the patients with benign biliary tract disease (control) and cholangiocarcinoma
Control
(n = 36)
Cholangiocarcinoma
(n = 44)
p value
Age (Yr) 54 ± 14.5 59 ± 12.9 0.130
Sex (Male:Female) 15:16 26:18 0.248#
Total bilirubin (mg/dL) 4.2 ± 5.53 14.6 ± 11.34 <0.001*
Direct bilirubin (mg/dL) 2.6 ± 3.75 10.3 ± 8.47 <0.001*
Albumin (g/dL) 3.8 ± 0.61 3.1 ± 0.68 0.050
Globulin (g/dL) 3.6 ± 0.73 4.1 ± 0.93 0.253
AST (U/L) 65.4 ± 53.80 183.9 ± 378.82 0.012*
ALT (U/L) 75.0 ± 77.72 101.4 ± 14.49 0.615
ALP (IU/L) 318.6 ± 349.65 551.8 ± 526.04 0.001*
Quantitative variables are presented as the means ± standard deviation. #; Pearson Chi-square was used to compare between two groups, *; the 
level of serum total bilirubin, direct bilirubin, AST and ALP were significantly higher in cholangiocarcinoma patients than in controls (Mann-Whitney 
U test; p < 0.05).BMC Gastroenterology 2009, 9:30 http://www.biomedcentral.com/1471-230X/9/30
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ROC curve analysis for CEA, CA19-9, MMP-9 and MMP-7 
for diagnosis of cholangiocarcinoma
An ROC curve analysis (Figure 2) was used to calculate an
area under the curve (AUC) of 0.63 (CI 95% 0.501 –
0.760) and of 0.63 (CI 95% 0.491 – 0.761) for CEA and
CA19-9, respectively. Additionally, an ROC curve analysis
was used to calculate an area under the curve of 0.59 (CI
95% 0.455 – 0.722) and of 0.73 (CI 95% 0.614 – 0.848)
for MMP-9 and MMP-7, respectively. When comparing
the AUC of the ROC curve for CEA, CA19-9, MMP-9 and
MMP-7 with a chance value equal to 0.5 (the worst value
of AUC of ROC), only the AUC of the ROC for MMP-7 is
significantly higher than 0.5 (p = 0.001). The sensitivity
and specificity for CEA, CA19-9, MMP-9 and MMP-7 are
presented in Table 2.
Due to the significant difference of the serum AST, ALP,
total bilirubin and direct bilirubin between the control
and cholangiocarcinoma patients, we investigated the cor-
relation between the values of these blood chemistries
and the values for CEA, CA19-9, MMP-9 and MMP-7. The
results showed that none of these parameters was signifi-
cantly correlated (p > 0.05) (see Addition file 1 and Addi-
tion file 2). To determine whether the values of serum
MMP-9 and MMP-7 were predictive of cholangiocarci-
noma independently of other tumor markers, we carried
out a logistic regression analysis. In a multivariable model
using MMP-9 (cut-off value = 15 ng/ml), MMP-7 (cut-off
value = 7.4 ng/ml), CEA (cut-off value = 5 ng/ml), CA19-
9 (cut-off value = 100 U/ml), MMP-9 (an adjusted odds
ratio = 3.76; 95% CI = 1.05–13.47; p = 0.04), MMP-7 (an
Serum levels of CEA, CA19-9, MMP-7 and MMP-9 in cholangiocarcinoma and control (benign biliary tract disease) patients Figure 1
Serum levels of CEA, CA19-9, MMP-7 and MMP-9 in cholangiocarcinoma and control (benign biliary tract dis-
ease) patients. Box plots comparing levels of CEA, CA19-9, MMP-7 and MMP-9 are demonstrated. Levels of MMP-7 and 
MMP-9 are presented as ng/ml, while CEA and CA19-9 are presented with the log data to accommodate the wide range. *; 
Only the value for MMP-7 between the two groups is significantly different (Student's t-test; p < 0.001).BMC Gastroenterology 2009, 9:30 http://www.biomedcentral.com/1471-230X/9/30
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adjusted odds ratio = 5.33; 95% CI = 1.55–18.31; p =
0.008) and CA19-9 (an adjusted odds ratio = 4.60; 95%
CI = 1.23–17.30; p = 0.02) were the independent predic-
tors of cholangiocarcinoma, whereas CEA was not.
Discussion
The need for better tests to diagnose and screen for
patients with cholangiocarcinoma is an important issue
that must be addressed to improve the treatment results
for these patients. Unfortunately, no specific serum tumor
markers have been identified for this disease.
Based on the results of our study, the sensitivity and spe-
cificity of CEA as a marker for detecting cholangiocarci-
noma are 58.54% and 62.50%, respectively. This is
consistent with previously published studies that reported
that the sensitivity and specificity of CEA for detecting
cholangiocarcinoma were 33–84% and 33–100%, respec-
ROC curve analyses of CEA, CA19-9, MMP-9 and MMP-7 for the diagnosis of cholangiocarcinoma Figure 2
ROC curve analyses of CEA, CA19-9, MMP-9 and MMP-7 for the diagnosis of cholangiocarcinoma. The diagnostic 
accuracy of each biomarker, in terms of its sensitivity and specificity, are presented by receiver operating characteristic (ROC) 
curve analysis. Figures 2A, 2B, 2C and 2D correspond to CEA, CA19-9, MMP-7 and MMP-9. Only the area under the 
curve (AUC) of the ROC for MMP-7 is significantly higher than a chance value (0.5).BMC Gastroenterology 2009, 9:30 http://www.biomedcentral.com/1471-230X/9/30
Page 6 of 8
(page number not for citation purposes)
tively [7,20]. Previous articles have addressed the accuracy
of CA19-9 in the identification of cholangiocarcinoma. A
previous study identified cholangiocarcinoma with a sen-
sitivity of 67.5% and a specificity of 86.8% when a cut-off
value of 100 U/ml for CA19-9 was used and a sensitivity
of 77.9% and a specificity of 76.3% when a cut-off value
of 35 U/ml for CA19-9 was used [10]. In our series, we
found that the sensitivity was 70.45% and the specificity
was 63.64% when using a cut-off value of 100 U/ml for
CA19-9. However, the AUC of the ROC curve for CA19-9
was only 0.63 in the discrimination of cholangiocarci-
noma in our study. Therefore, when the cut-off value was
changed to 35 U/ml, the specificity markedly decreased
(81.82% of sensitivity and 48.48% of specificity). We sug-
gest that the differences among the patients should be
concerned. In the study published by John, A. R., et al, 25
patients with benign liver tumors and 13 patients with
benign bile duct strictures were used as a control group
[10]. However, in our studies, all the subjects in the con-
trol group had been diagnosed with benign bile duct dis-
eases. The reason that we used patients with benign bile
duct diseases as a control group was because the symp-
toms of cholangiocarcinoma are similar to the symptoms
of benign bile duct diseases in our clinical setting.
We observed that most of the cholangiocarcinoma
patients were suffering from the invasiveness of the
cholangiocarcinoma cells into the adjacent organs. The
mechanism by which cancer cells invade the surrounding
tissue requires the breakdown of the extracellular matrix
and the subsequent migration of the cancerous cells
through the degraded structures [14]. Because extracellu-
lar matrix remodeling is the major activity of a family of
enzymes known as matrix metalloproteinases (MMPs),
these enzymes were investigated for their contributions to
the malignant phenotype in cholangiocarcinoma
patients. Previous studies have demonstrated that the
expression of MMP-9 and MMP-7 can be detected in
cholangiocarcinoma specimens [21-23]. Therefore, in our
study, the accuracy of serum MMP-9 and MMP-7 levels
were investigated in an effort to find a reliable serum
marker that can discriminate the benign biliary tract dis-
eases from cholangiocarcinoma.
There are numerous studies that demonstrate that the
serum level of MMP-9 is significantly elevated in many
types of cancers, including breast cancer, esophageal can-
cer, and lung cancer [24-26], but previous reports have
shown that the incidence of MMP-9 expression in cholan-
giocarcinoma specimens is only 9–47.5% [15,22]. Our
study demonstrated that there is no statistically significant
difference in the serum MMP-9 levels between cholangi-
ocarcinoma patients and control patients. Previous stud-
ies revealed that detection of MMP-9 in serum is an
artifact representing the release of MMP-9 from leukocytes
during the clotting process in the blood collection tube
[27,28]. The role of circulating MMP-9 in diagnosing
cholangiocarcinoma should be further investigated by
collecting the plasma instead of serum and the assay
should be performed without long delay [29].
Previous studies have demonstrated that cholangiocarci-
noma specimens frequently express MMP-7 (75.8–100%)
[15,21]. As far as we are aware, no other published inves-
tigation is available that uses the serum MMP-7 level to
diagnose cholangiocarcinoma. Our study shows that the
serum MMP-7 level is significantly higher in patients with
cholangiocarcinoma than with benign biliary tract dis-
Table 2: Performance of the biomarkers for the diagnosis of cholangiocarcinoma
Biomarker (cut-off value) Sensitivity (%) (95% CI) Specificity (%) (95% CI) PLR (95% CI) NLR (95% CI)
CEA
(3 ng/ml)
70.73
(55.52–82.39)
43.75
(28.17–60.67)
1.26
(0.87–1.81)
0.67
(0.36–1.24)
CEA
(5 ng/ml)
58.54
(43.37–72.24)
62.50
(45.25–77.07)
1.56
(0.93–2.62)
0.66
(0.42–1.04)
CA19-9
(35 U/ml)
81.82
(68.04–90.49)
48.48
(32.50–64.78)
1.59
(1.11–2.27)
0.38
(0.18–0.77)
CA19-9
(100 U/ml)
70.45
(55.78 – 81.84)
63.64
(46.62–77.81)
1.94
(1.19–3.16)
0.46
(0.28–0.78)
MMP-9
(15.0 ng/ml)
63.64
(48.87–76.22)
41.94
(26.42–59.23)
1.67
(0.93–3.01)
0.59
(0.35–0.98)
MMP-9
(20.0 ng/ml)
34.10
(21.88–48.86)
74.19
(56.75–86.30)
1.32
(0.64–2.73)
0.89
(0.66–1.20)
MMP-7
(6.0 ng/ml)
76.32
(60.79–87.01)
46.88
(30.87–63.55)
1.44
(0.99–2.08)
0.51
(0.26–1.00)
MMP-7
(7.4 ng/ml)
63.16
(47.28–76.62)
71.88
(54.63–84.44)
2.25
(1.23–4.11)
0.51
(0.32–0.82)
The sensitivity, specificity, positive and negative likelihood ratio (LR) as well as their 95% confidence interval (CI) for each marker is presented. The 
likelihood ratio is the ratio of true and false positives (sensitivity and 1-specificity respectively), where the higher values reflect the probability of a 
better performance. (PLR, positive likelihood ratio; NLR, negative likelihood ratio; 95% CI, 95% confidence interval)BMC Gastroenterology 2009, 9:30 http://www.biomedcentral.com/1471-230X/9/30
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eases. MMP-7 is the smallest of the MMPs and has been
demonstrated to degrade or process a variety of matrix
and nonmatrix molecules. Unlike most MMPs, which are
expressed by stromal cells, MMP-7 is principally expressed
by epithelial cells [30]. A previous study reported that the
serum MMP-7 level was significantly elevated in patients
with ovarian cancer and advanced colorectal cancer
[16,31]. We suggest that MMP-7 might be detected in
many cancers that originate from epithelial cells. In addi-
tion, we also found that the accuracy of the serum MMP-
7 level for the diagnosis of cholangiocarcinoma is better
than the serum level of MMP-9, CEA and CA19-9, as
observed by calculating the AUC of the ROC curve. Only
the AUC of the ROC curve for the serum MMP-7 level is
significantly higher than a chance value (0.5). Our study
demonstrated that use of serum MMP-7 could identify
cholangiocarcinoma patients from benign biliary tract
disease patients. However, further larger prospective stud-
ies that evaluated the benefit of serum MMP-7 in helping
the physician to take decisions on diagnosis cholangiocar-
cinoma are necessary before the implementation of using
serum MMP-7 as a marker for cholangiocarcinoma. Previ-
ous studies determined that expression of MMP-7 in
cholangiocarcinoma is an unfavorable postoperative
prognostic factor for cholangiocarcinoma patients [15].
However, in this study, most of the cholangiocarcinoma
patients had been diagnosed with unresectable tumors;
only five patients underwent curative resection (R0).
Therefore, an analysis for a prognostic factor of cholangi-
ocarcinoma could not be clarified. Further studies that
include many cases of resectable cholangiocarcinoma
need to be completed before the serum MMP-7 level can
be used as a prognostic factor for cholangiocarcinoma.
Conclusion
The elevation of serum MMP-7 levels could be a very use-
ful tool for the detection of cholangiocarcinoma, espe-
cially in those patients with obstructive jaundice.
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